Market Cap
₹31,517 Cr.
P/E
64.02
About
Syngene International Limited, founded in 1993, is a globally recognized contract research and manufacturing firm. It offers a wide range of services supporting research and development projects, from… Read more
Syngene International Limited, founded in 1993, is a globally recognized contract research and… Read more
Low
608
52W Range
High
860
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Forensics

11 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE
Latest
11.98%
3yr Average
12.27%
5yr Average
14.02%
Net Profit Margin
Latest
14.62%
3yr Average
14.79%
5yr Average
16.68%
ROCE
Latest
13.67%
3yr Average
13.42%
5yr Average
14.42%
Debt to Equity
Latest
0.03
3yr Average
0.14
5yr Average
0.2
Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Peer Comparison
Suppliers
  • HLE Glascoat Ltd.
Customers
  • Procter & Gamble Health Ltd.
  • Amgen
  • Bristol-Myers Squibb
  • Abbvie
  • Albireo
FAQs on Syngene International Ltd. Business

Syngene International Limited, established in 1993, is a renowned CRMO offering integrated drug discovery and development services. With various certifications and accreditations, the company provides support from lead generation to clinical supplies.

Syngene Internation. major competitors are Piramal Pharma, Laurus Labs, Sun Pharma Adv. Res, Dishman Carbogen Amc, Zenotech Laboratorie, Jeevan Scientific, Vivo Bio Tech.
Market Cap of Syngene Internation. is ₹31,517 Crs.
While the median market cap of its peers are ₹2,637 Crs.

Syngene Internation. seems to be financially stable compared to its peers.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate peers.

Company Filing
2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release Mar Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Investor Presentation Mar Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Conference Call Mar Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Jun Mar Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Discussions & Analysis